This guide is educational, not a recommendation to use tesamorelin. It contains no dosing or treatment instructions. Sources checked November 4, 2026. No clinician review is claimed.
“Reduces belly fat” sounds straightforward until you ask which fat, in whom, and compared with what. Tesamorelin has real randomized human trials. The problem is not that all its evidence comes from animals. It is that a specific finding is often stretched into a promise about anyone who wants a leaner waist.
The useful answer separates three questions: what is approved, what researchers measured, and which claims still go beyond those measurements.
What is tesamorelin approved for?
In the United States, Egrifta WR is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its label explicitly says it is not indicated for weight-loss management. Egrifta WR and Egrifta SV are different formulations and are not substitutable. Those product distinctions should not disappear when an article simply says “tesamorelin.” Current Egrifta WR prescribing information
An approved indication is a defined use in a defined population. It is not a blanket endorsement of every product using the same ingredient name or every fitness claim attached to it.
Why does visceral versus subcutaneous fat matter?
Visceral fat is inside the abdomen around internal organs. Subcutaneous fat sits beneath the skin. The distinction is more than vocabulary: a treatment can change one compartment without producing the same change in the other.
A major 2007 trial used CT imaging to measure visceral fat, rather than relying on a scale or before-and-after photograph. It randomized 412 adults with HIV and abdominal fat accumulation to subcutaneous tesamorelin or placebo for 26 weeks; 86% were men. Visceral fat decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group. Falutz and colleagues, 2007
That was not a 15.2% reduction in body weight. It was the reported change in an imaging-based measure of visceral fat in a particular trial population. Converting that number into pounds lost, a guaranteed waist change or a promise to remove lower-belly fat would change what the study actually found.
How does tesamorelin work?
Tesamorelin mimics growth hormone-releasing hormone. It stimulates the body's growth hormone pathway and raises insulin-like growth factor 1, or IGF-1. This is a hormonal mechanism, not a substance physically selecting and dissolving a visible patch of fat. Prescribing information, sections 12.1–12.2
A plausible mechanism helps explain why researchers tested a drug. It does not replace the results of those tests or establish every benefit proposed online. Our CJC-1295 and ipamorelin evidence guide explains the related distinction between changing a hormone measurement and demonstrating a useful clinical outcome.
Has tesamorelin been studied in people without HIV?
Yes. Saying there is no human research outside HIV would be wrong.
A 2012 randomized, double-blind trial enrolled 60 adults with abdominal obesity and reduced growth hormone secretion. Over 12 months, the estimated treatment difference in visceral fat area was −35 cm², with a 95% confidence interval of −58 to −12 cm². There was no statistically significant effect on abdominal subcutaneous fat. Makimura and colleagues, 2012
The selection criteria matter. These were not simply any 60 people who wanted to lose belly fat. They had abdominal obesity and reduced growth hormone secretion. The study provides evidence in that selected group, but does not establish the same benefit for lean athletes, people with ordinary hormone secretion or everyone with fat beneath the skin.
The paper also reported changes in cardiovascular risk markers, including an ultrasound measure of carotid artery thickness. A change in such a marker is not the same as demonstrating fewer heart attacks or strokes. The trial's size and outcomes should stay attached to any summary of its findings. Trial report
What about liver fat?
Liver fat is another distinct outcome. In a 2019 randomized trial in people with HIV and non-alcoholic fatty liver disease, 61 participants were enrolled and 60 received study treatment. Researchers compared tesamorelin with placebo over 12 months using liver-fat measurements and other assessments. Stanley and colleagues, 2019
The estimated between-group effect on hepatic fat fraction was −4.1 percentage points. Expressed as change relative to baseline, the estimated treatment effect was −37% versus placebo. Those are two ways of expressing the liver-fat result, not two separate benefits and not 37% body-weight loss. This was a study of people with both HIV and fatty liver disease. It does not establish a general-purpose treatment for fatty liver in every population. Full trial
Does the fat reduction last after treatment stops?
The follow-up to the earlier HIV trial examined what happened over 52 weeks and when participants stopped tesamorelin. Visceral-fat reductions were sustained in those continuing treatment, while visceral fat reaccumulated after discontinuation. Falutz and colleagues, 2008
That result matters when a short before-and-after story implies a permanent change. A study can show an effect during treatment without showing that it remains after treatment ends. This finding is not a recommendation to continue, stop or restart a medicine; those decisions need individual clinical assessment.
What safety issues are important?
The current label warns about elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity. It lists contraindications including active malignancy, pregnancy and specified hypothalamic-pituitary disorders. Long-term cardiovascular safety has not been established. These are reasons this is a prescription treatment requiring clinical assessment, not a casual cosmetic experiment. Prescribing information, sections 1, 4 and 5
A small trial reporting reassuring average glucose results cannot erase a warning drawn from a wider evidence base. Likewise, an adverse event reported during a trial does not automatically establish causation. Read the population, follow-up period and comparison group together rather than choosing whichever sentence sounds most reassuring or alarming.
How to judge the next tesamorelin claim
Ask what “works” means in the claim:
- Does it refer to visceral fat, subcutaneous fat, liver fat or total body weight?
- Were the participants similar to the population being advertised to?
- Is the percentage an actual treatment-group change, a difference versus placebo or a relative change in a different measurement?
- Was the benefit measured only during treatment, or after stopping too?
- Does the claim distinguish an approved product and indication from a broad promise?
Tesamorelin is a good example of why peptide information needs more than a simple “proven” or “unproven” label. There are human findings worth understanding, and clear limits to what they demonstrate.
If you already use a peptide, Jabful can help you organize your tracking records. A log is not a test of treatment effectiveness or safety, and the app does not decide whether a medicine is appropriate for you.